iCone Consortium set up by MaSTherCell SA hits a major milestone in the development of an industrial process for large scale production of human iPSC-derived cortical neurons
The iCone (iPSC-derived Cortical neurons) Consortium made up of MaSTherCell SA (CDMO dedicated to industrialisation and production of Cell and Gene Therapies), Ncardia (a drug discovery and development company specialised in testing drug candidates in stem cell derived cardiomyocyte and neuron models), the Pierre Vanderhaeghen Lab. at the Université Libre de Bruxelles (specialised in research on cortical neuron development from human ES and iPS cells) and the “Laboratoire de Chimie Analytique Pharmaceutique” led by Philippe Hubert at Université de Liège (ULiège, CIRM, Vibra-santé Hub - specialized in “Quality by Design” and vibrational spectroscopy) has just reached a major milestone in the development of a 3D mid- and large-scale process for the production of human iPSC-derived cortical neurons.
MaSTherCell Announces a New Commercial Manufacturing Plant for Cell & Gene Therapies
GOSSELIES, BELGIUM – March 26, 2019 – MaSTherCell S.A. a subsidiary of Masthercell Global Inc., a cell and gene therapy-dedicated Contract Development and Manufacturing Organization (CDMO) announces today that it has signed a lease agreement for a 5,700m2 (61,354ft²) facility located in Belgium. The new facility will become a state-of-the-art manufacturing and production site designed for late-stage and commercially-approved cell and gene therapy products. The commercial facility is expected to be operational in early 2021.
MaSTherCell Global Announces Promotions of Darren Head as Chief Executive Officer and Dr. Denis Bedoret as President
GREENWICH, CT and CHARLEROI, BELGIUM - January 25, 2019 - Great Point Partners, LLC (“Great Point”), a Greenwich-based private investment firm focused on the health care industry and MaSTherCell Global, Inc. (“MaSTherCell Global”), a portfolio company and strategic partner of Great Point, today announced executive promotions at MaSTherCell Global effective January 1, 2019.
Great Point Partners-Backed Strategic Partner MaSTherCell Global Announces Achievement of First Milestone Funding and Expansion with New Facility in Houston, Texas
GREENWICH, CT and HOUSTON, TX - January 25, 2019 - Great Point Partners, LLC (“Great Point”), a Greenwich-based private investment firm focused on the health care industry, announces today that its portfolio company and strategic partner MaSTherCell Global, Inc. (“MaSTherCell Global”) achieved its first financial milestone targets and as a result Great Point has funded $6.6 million of growth equity to the company’s balance sheet.
MaSTherCell expands production by doubling its capacity
GOSSELIES, BELGIUM – November 30, 2018 – MaSTherCell S.A. a subsidiary of Orgenesis Inc. (NASDAQ: ORGS) through Masthercell Global Inc., a cell therapy-dedicated Contract Development and Manufacturing Organization (CDMO) launched a new production wing of 600 m² at its Belgium site in the presence of the Minister-President of Wallonia, Willy Borsus. Masthercell is also backed by Great Point Partners, LLC (“GPP”), a leading healthcare investment firm based in Greenwich, Connecticut.
Iovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe
SAN CARLOS, CA and GOSSELIES, BELGIUM – October 18, 2018 – Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte (TIL) technology, and MaSTherCell S.A. a subsidiary of Orgenesis Inc. (NASDAQ: ORGS) through Masthercell Global Inc., a cell therapy-dedicated Contract Development and Manufacturing Organization (CDMO) today announced that the two companies have entered into a new three-year Manufacturing Services Agreement. MaSTherCell will manufacture TIL for Iovance’s European late-stage clinical trials in its commercial-ready cGMP manufacturing suites.